Literature DB >> 1460120

Guidelines for optimal use of isotretinoin in acne.

A M Layton1, W J Cunliffe.   

Abstract

Isotretinoin is most effective for patients with acne who fail to respond to other forms of treatment; virtually all patients respond to isotretinoin, 0.5 to 1.0 mg/kg/day. As many as 61% of patients are cured after one course, but 39% require further isotretinoin (16%) or oral antibiotics (23%). The relapse rate can be reduced by the administration of the higher dose of 1 mg/kg/day (thus achieving a significant cumulative dose of > 120 mg/kg), especially to young patients and men with truncal acne and more severe disease. About 85% require a 4-month course, but 15% require longer treatment, with some up to 10 months. There are several reasons for a slow response to treatment, including the presence of macrocomedones, ovarian dysfunction, and as-yet unknown factors. Macrocomedones can be treated with light cautery, ovarian dysfunction with hormonal therapies, and in those persons who have no obvious explanation for slow response, persistence with isotretinoin alone is required. Repeat courses of isotretinoin can also be given. Six years ago most patients treated with isotretinoin had severe acne (60%), but today most patients (60%) have therapy-resistant moderate acne. Isotretinoin is a consideration in such patients to reduce the physical and psychological effects of acne, particularly because there is no simple method to treat acne scars.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1460120     DOI: 10.1016/s0190-9622(08)80252-6

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  11 in total

1.  Drug-cyclodextrin-vesicles dual carrier approach for skin targeting of anti-acne agent.

Authors:  Navjot Kaur; Richa Puri; Subheet Kumar Jain
Journal:  AAPS PharmSciTech       Date:  2010-03-24       Impact factor: 3.246

2.  Flexible liposomal gel dual-loaded with all-trans retinoic acid and betamethasone for enhanced therapeutic efficiency of psoriasis.

Authors:  Wei Wang; Gao-Feng Shu; Kong-Jun Lu; Xiao-Ling Xu; Min-Cheng Sun; Jing Qi; Qiao-Ling Huang; Wei-Qiang Tan; Yong-Zhong Du
Journal:  J Nanobiotechnology       Date:  2020-05-24       Impact factor: 10.435

Review 3.  Acne vulgaris.

Authors:  E Healy; N Simpson
Journal:  BMJ       Date:  1994-03-26

Review 4.  Guidelines for the management of acne vulgaris in adolescents.

Authors:  Victoria Goulden
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

5.  UVA is the major contributor to the photodegradation of tretinoin and isotretinoin: Implications for development of improved pharmaceutical formulations.

Authors:  Bassam M Tashtoush; Elaine L Jacobson; Myron K Jacobson
Journal:  Int J Pharm       Date:  2007-11-04       Impact factor: 5.875

6.  Retinoic acid 4-hydroxylase inducibility and clinical response to isotretinoin in patients with acne.

Authors:  Frank Wang; Heh Shin R Kwak; Nada Elbuluk; Anya L Kaczmarek; Ted Hamilton; John J Voorhees; Gary J Fisher; Sewon Kang
Journal:  J Am Acad Dermatol       Date:  2009-06-13       Impact factor: 11.527

7.  Face to face with oral isotretinoin: a closer look at the spectrum of therapeutic outcomes and why some patients need repeated courses.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2012-11

Review 8.  Acne. A review of optimum treatment.

Authors:  N L Sykes; G F Webster
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

9.  The rates of major malformations after gestational exposure to isotretinoin: a systematic review and meta-analysis.

Authors:  Eun Jeong Choi; NaeRy Kim; Ho-Seok Kwak; Hae Ji Han; Kyoung-Chul Chun; Young-Ah Kim; Jae-Whoan Koh; Jung Yeol Han; Sung Hong Joo; Ji Sung Lee; Gideon Koren
Journal:  Obstet Gynecol Sci       Date:  2021-03-17

10.  Treatment of plane warts with a low-dose oral isotretinoin.

Authors:  Hayder R Al-Hamamy; Husam Ali Salman; Nawar A Abdulsattar
Journal:  ISRN Dermatol       Date:  2012-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.